

## FLUOCINOLONE intravitreal implant (Iluvien®) for non-infectious uveitis

**The Pan Mersey Area Prescribing Committee recommends the prescribing of FLUOCINOLONE intravitreal implant (Iluvien®), by specialists only, for the treatment of recurrent non-infectious uveitis in accordance with NICE TA590.**

**RED**

[NICE TA590](#) (31 July 2019) recommends fluocinolone acetonide intravitreal implant, within its marketing authorisation, as an option for preventing relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. It is recommended only if the company provides it according to the commercial arrangement.<sup>[1]</sup>

NICE do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).

### References

1. National Institute for Health and Care Excellence. Technology Appraisal 590: [Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis](#), 31 July 2019. Accessed 07 August 2019.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.